While the global stock market improves, Bristol Myers Squibb (BMY) has been experiencing a decline. Nonetheless, BMY celebrates the 10th anniversary of its Unregistered Trademark Opdivo, receiving FDA approval for its subcutaneous version. This pharmaceutical giant recently presented at the J.P. Morgan's 43rd Annual Healthcare Conference and revealed positive results from two pivotal Phase 3 Trials assessing Sotyktu (deucravacitinib) amongst adults with psoriatic arthritis. However, the company did not meet investors' expectations with a mere 2.4% return over the last five years. In 2024, BMY started the year off with various FDA approved drugs alongside Vertex and Novo. Fresh reports indicate significant drug price increases in 2025 by Pfizer, BMY, and others. BMY is also involved in a legal dispute with investors from Padlock Therapeutics concerning 'milestone' payments. Nevertheless, their continuous research and innovation have been instrumental in revolutionizing patient treatment, especially evident through the fda approved Opdivo Qvantig™ (nivolumab and hyaluronidase-nvhy) Injection for Most Previously Approved Adult, Solid Tumor Opdivo® (nivolumab) Indications. Their commitment to advanced technology and research, along with fostering inclusivity/diversity, has made a global impact on the BioPharma industry.
Bristol-Myers Squibb News Analytics from Tue, 19 Mar 2024 07:00:00 GMT to Sat, 04 Jan 2025 11:08:31 GMT -
Rating 2
- Innovation 2
- Information 3
- Rumor 6
